EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
This record was last updated July 17, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19).
The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.
Protocol Amendment History
37 amendments
This ClinicalTrials.gov record has been amended 37 times since 2022-02-28; most recent amendment 2025-07-16.
Status change: Suspended → Recruiting2024-11-01
Status change: Recruiting → Suspended2024-08-15
Status change: Suspended → Recruiting2024-06-03
Status change: Recruiting → Suspended2024-01-30
Status change: Suspended → Recruiting2023-06-02
Status change: Recruiting → Suspended2023-03-03
Status change: Not Yet Recruiting → Recruiting2022-03-16